Skip to main content

Cellworks Taps Semiconductor Expertise to Boost Predictability

With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks Group Inc. is advancing lead drug CWG952 toward the clinic for rheumatoid arthritis.

STAY INFORMED

Top